katie8288Feb 7, 20220 min readuniQure Announces Dosing of First Patients in Europe Open-Label Trial of AMT-130
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
Comments